Abiraterone Mylan 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0007 
Minor change in labelling or package leaflet not 
05/09/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0006/G 
This was an application for a group of variations. 
23/08/2023 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.b.1.h - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition or 
replacement (excl. Biol. or immunol. substance) of a 
specification parameter as a result of a safety or 
quality issue 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.a.3.b - Change in batch size (including batch size 
ranges) of AS or intermediate - Downscaling down to 
10-fold 
IB/0004 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
13/06/2023 
SmPC and PL 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0005 
B.II.d.2.a - Change in test procedure for the finished 
24/04/2023 
n/a 
product - Minor changes to an approved test 
procedure 
N/0003 
Minor change in labelling or package leaflet not 
15/06/2022 
24/03/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0002/G 
This was an application for a group of variations. 
30/05/2022 
n/a 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
IB/0001/G 
This was an application for a group of variations. 
04/02/2022 
24/03/2023 
SmPC, 
Labelling and 
PL 
B.II.e.1.b.1 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Page 3/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
